Zobrazeno 1 - 10 of 14 pro vyhledávání: '"J. I. Chacón"'
1
Akademický článek
BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study
Autor: A. Barnadas, M. Muñoz, M. Margelí, J. I. Chacón, J. Cassinello, S. Antolin, E. Adrover, M. Ramos, E. Carrasco, M. A. Jimeno, B. Ojeda, X. González, S. González, M. Constenla, J. Florián, A. Miguel, A. Llombart, A. Lluch, M. Ruiz-Borrego, R. Colomer, S. Del Barco, On behalf of GEICAM, Spanish Breast Cancer Group
Publikováno v: Journal of Patient-Reported Outcomes, Vol 3, Iss 1, Pp 1-10 (2019)
Abstract Background Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Qual
Externí odkaz: https://doaj.org/article/7ececc69e4694658bd1cea7449c6ee4c
Zobrazit plný text záznamu
2
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
Autor: M. Bellet Ezquerra, S. Antolin Novoa, Mafalda Oliveira, E. Martínez de Dueñas, S. López-Tarruella Cobo, M. A. Segui Palmer, L. de la Cruz Merino, J. Gavila Gregori, I. Álvarez López, J. I. Chacón López-Muñiz
Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname
Scientia
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya
Clinical & Translational Oncology
Recurrència loco-regional; Càncer de mama; Pautes Recurrencia loco-regional; Cáncer de mama; Pautas Loco-regional recurrence; Breast cancer; Guidelines Although the metastasic breast cancer is still an incurable disease, recent advances have incre
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c99ab8f97d50d5114bc5b368698614ee
http://hdl.handle.net/10261/212722
Zobrazit plný text záznamu
3
Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen
Autor: Jaime Feliu, Y. Escobar, Javier de Castro, C. Jara, J. I. Chacón, Amalio Ordóñez, M. Gonzáles Barón, A. Colmenarejo, Enrique Espinosa, Javier Cassinello Espinosa, Pilar Garrido, C. García Girón
Publikováno v: Cancer Chemotherapy and Pharmacology. 38:191-194
A phase II study was performed to assess the efficacy and toxicity of the combination of cisplatin (CDDP) and tamoxifen (TAM) in patients with metastatic malignant melanoma (MM). A total of 31 consecutive previously untreated patients with unresectab
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2201c595393e47593e6f9b16ade44994
https://doi.org/10.1007/s002800050469
Zobrazit plný text záznamu
4
Non-Small-Cell Lung Cancer (NSCLC)
Autor: J. Feliu, Angel Artal, García de Paredes Ml, García Girón C, P. Zamora, Amalio Ordóñez, Pilar Garrido, J. I. Chacón, González Barón M
Publikováno v: American Journal of Clinical Oncology. 15:23-28
This is a review of the therapeutic schedules used in our service during the past 10 years for the therapy of advanced non-small-cell lung cancer. During the first years, nonran-domized trials were conducted and several combinations were tested: MACC
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::453bd360d82c10d384b43cf902853be2
https://doi.org/10.1097/00000421-199202000-00005
Zobrazit plný text záznamu
5
Antiemetic Regimens in Outpatients Receiving Cisplatin and Non-Cisplatin Chemotherapy: A Randomized Trial Comparing High-Dose Metoclopramide Plus Methylprednisolone with and Without Lorazepam
Autor: P. Zamora, C Herranz, M L García de Paredes, C. García Girón, M. González Barón, Angel Artal, J. Feliu, A. Ordóñez Gallego, J. I. Chacón, Pilar Garrido
Publikováno v: Acta Oncologica. 30:623-627
Results of a randomized trial on antiemesis for cisplatin (CDDP) and non-CDDP chemotherapy-induced vomiting are reported. One hundred and sixty-three outpatients received 282 chemotherapy courses (141 with CDDP and 141 without CDDP). Patients were ra
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c6daa80aa127a570e7972aacbece81a
https://doi.org/10.3109/02841869109092430
Zobrazit plný text záznamu
6
[Comparative study of the survival of gastric B-cell lymphoma of mucosal origin with respect to lymph node lymphoma of similar histology]
Autor: M A, Cruz, J L, Orradre, J, Berruga, B, Martínez, J I, Chacón, M A, Piris
Publikováno v: Medicina clinica. 99(13)
The differences in clinical presentation, morphology, phenotype and genetic changes between lymphomas originating in the gastrointestinal tract and the lymph nodes justified the proposal of a system of specific classification for lymphomas originatin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::94aee575cf63e99b8357ef2c55cd58ab
https://pubmed.ncbi.nlm.nih.gov/8315967
Zobrazit plný text záznamu
9
A randomized, phase II trial comparing sequential paclitaxel/cisplatin/gemcitabine/vinorelbine/ (PCGV) with cisplatin/gemcitabine/vinorelbine/ (CGV) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Autor: J. Feliu, Cristobal Belda-Iniesta, C. Madroñal, Manuel González-Barón, Carlos Poblete Jara, G. Martin, J. de Castro, E. Casado Saenz, J. C. Torrego, María Sereno, J. I. Chacón
Publikováno v: Journal of Clinical Oncology. 24:17008-17008
17008 Background: New effective therapies are needed to improve the outcome of patients with advanced NSCLC. In this regard, new approaches such as cisplatin-based triplets have been explored with promising results but high toxicity. Furthermore, seq
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::12a5919161d99ad21f4b89acfa122bc1
https://doi.org/10.1200/jco.2006.24.18_suppl.17008
Zobrazit plný text záznamu
10
Oxaliplatin (Ox) and raltitrexed (Ral) as first line treatment for locally advanced and metastatic gastric adenocarcinoma: Results of an ONCOPAZ phase II trial (OPHA 0141)
Autor: José Ángel García Sáenz, M. Bolaños, Pilar Escudero, J. R. Mel, J. I. Chacón, M. G. Baron, J. M. Vicent, J. Feliu, E. Fonseca, L. M. Anton
Publikováno v: Journal of Clinical Oncology. 22:4213-4213
4213 Background: No data exist about efficacy of the combination of Ox and Ral for treatment of advanced gastric adenocarcinoma, a doublet that might be active in this disease. Methods: A multicenter phase II trial was launched in Aug 2002. Primary o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::03d9c9083538f375e6ebcc3911617914
https://doi.org/10.1200/jco.2004.22.90140.4213
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje